🚀 A Rare Cancer Therapy Breakthrough and a Bold Capital Plan

Unsubscribe

A message from Market Jar, Inc

Hey there,

A breakthrough approach in cancer treatment is catching fresh attention ahead of tomorrow's open — and the setup is unusual.

Here's What We Know So Far:

Low Float: Just under 12M shares outstanding — making it sensitive to news.
Pipeline Potential: Developing a next-gen therapy designed to make today's top immunotherapies work better, without the safety issues that derailed past attempts.
Capital Strategy: Reviewing creation of a $500M digital asset investment arm to keep the pipeline fully funded without heavy dilution.
Market Precedent: Similar therapies have attracted billion-dollar buyouts from major pharma.
Dual Markets: Targeting both cancer immunotherapy and artificial blood — each multi-billion-dollar opportunities.

Why It's Back on the Radar Now:

Multiple catalysts are lining up over the next 12–18 months, including regulatory milestones and potential partnership announcements. With a float this small, history shows it can move quickly when headlines land.

7 Reasons It Has Our Attention Right Now:

Safer, more targeted cancer therapy approach.
Two high-growth market opportunities.
Low-float volatility potential.
Bold, non-dilutive funding plan.
History of sharp price moves on news.
M&A interest precedent in this drug class.
Regulatory filings on the horizon.

As always, the market will decide what's next.

Consider starting your research tonight. Tap here.

This message is a PAID ADVERTISEMENT for Liminatus Pharma Inc (NASDAQ:LIMN) from Market Jar Media Inc. StockEarnings, Inc. has received a fixed fee of $25000 from Market Jar Media Inc for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between August 14, 2025 and August 21, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either Liminatus Pharma Inc (NASDAQ:LIMN) or Market Jar Media Inc. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Liminatus Pharma Inc (NASDAQ:LIMN) on TradingWhisperer website for additional information about the relationship between Market Jar Media Inc and Liminatus Pharma Inc (NASDAQ:LIMN).

Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.

StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com

🚀 A Rare Cancer Therapy Breakthrough and a Bold Capital Plan

Post a Comment

Contact Form